← Back

AtriCure Inc

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Price · split & dividend adjusted
News & notes moving ATRC
Aging Population▲

Atrial Fibrillation Device Market to Reach $29B by 2035

The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.
ATRC ▲ABT ▲BSX ▲JNJ ▲MDT ▲
Aging Population ▲Biotech & Genomic Medicine ▲
Yahoo Finance·22hRead more ▾
ATRC

AtriCure Files Shelf Registrations for Employee Stock Offerings Totaling Up to $78.8 Million

AtriCure has filed two shelf registrations related to employee stock ownership offerings, covering up to 2,250,000 common shares and approximately US$78.8 million in potential issuance capacity. The filings come as the stock posted a 42.47% 30-day share price return and a 16.40% one-year total shareholder return, though longer-term three- and five-year returns remain weaker. Valuation narratives diverge sharply: one popular view pegs fair value at $47.00 against a recent close of $40.89, implying the stock is undervalued, while a discounted cash flow model estimates fair value at just $0.73, suggesting significant overvaluation. Key drivers include rapid revenue growth from minimally invasive devices like the AtriClip FLEX Mini and cryoSPHERE MAX, balanced against risks from rising competition and heavy R&D spending that may limit margin progress.
ATRC
Simply Wall St·28dRead more ▾
ATRC▲2

AtriCure beats Q2 estimates with $153.6 million revenue and $0.18 adjusted EPS

AtriCure reported second-quarter fiscal 2026 results that beat consensus estimates, with revenue of $153.6 million and adjusted earnings per share of $0.18. Revenue exceeded expectations by $1.79 million and adjusted EPS surpassed forecasts by $0.16, an 800% beat. The company swung to a net income of $9 million from a net loss of $6.2 million a year earlier, while adjusted EBITDA reached $27 million. Gross margin expanded 270 basis points to 77.2%, driven by product innovation, geographic mix, and efficiencies. Management raised full-year revenue guidance to $602 million to $610 million and adjusted EBITDA guidance to $85 million to $89 million, with EPS expected between $0.05 and $0.13.
ATRC ▲
Insider Monkey·29dRead more ▾
ATRC▲

AtriCure shares jump 6.2% after management reaffirms $1 billion revenue goal

AtriCure shares surged 6.2% to close at $28.80 in the last trading session on heavy volume. The rally followed the company's presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its target of reaching $1 billion in revenue by 2030 and highlighted the market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials. Investors also reacted to news of accelerated enrollment in the BoxX-NoAF trial, which could significantly broaden the company's addressable market if outcomes are positive. The stock currently carries a Zacks Rank of 3, or Hold.
ATRC ▲
Zacks Investment Research·68dRead more ▾
© 2026 MarketDXAsset